Cemiplimab is a novel programmed death-1 inhibitor recently approved for advanced cutaneous squamous cell carcinoma. Immune-related adverse events derived from cemiplimab are similar to other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results